تأثیر ضد شیگلایی ترکیب کورکومین زردچوبه
محورهای موضوعی : فصلنامه کیفیت و ماندگاری تولیدات کشاورزی و مواد غذایی
نگین سادات میرعشقی
1
(دانشجوی کارشناسی ارشد، گروه میکروبیولوژی، واحد اراک، دانشگاه آزاد اسلامی، اراک، ایران)
زهره جعفری
2
(استادیار، گروه میکروبیولوژی، باشگاه پژوهشگران جوان و نخبگان، واحد اراک، دانشگاه آزاد اسلامی، اراک، ایران)
بهروز شجاعی سعدی
3
(مربی، گـروه میکروبیولـوژی، واحــد اراک، دانشــگاه آزاد اسلامی، اراک، ایران)
کلید واژه: شیگلوز, مسمومیت غذایی, دیسانتری, کورکومین, شیگلا,
چکیده مقاله :
شیگلا باکتری هایی گرم منفی، بدون حرکت و اسپور می باشند که بیماری به نام شیگلوز یا اسهال خونی باسیلی را ایجاد می کنند. شیگلا به دلیل دوز عفونی کم (100 – 10 عدد باکتری) و عوارض بالا، افزایش سویه های مقاوم به آنتی بیوتیک ها قابل توجه هستند. بیماری شیگلوز دومین عامل اصلی مرگ و میر در کودکان زیر 5 سال می باشد. تشخیص به موقع و درمان آنتی بیوتیکی در کاهش عوارض و مرگ و میر نقش اساسی دارد. کورکومین یک ترکیب فنولی استخراج شده از زردچوبه می باشد که خواص فارماکولوژیک و آنتی باکتریال زردچوبه به دلیل وجود این ترکیب می باشد. مطالعات اخیر نشان داده است که کورکومین در دوزهای مناسب باعث مهار رشد شیگلا می شود. هدف از این مطالعه بررسی اثر ضد شیگلایی ترکیب کورکومین می باشد. مطالعه حاضریک پژوهش مروری می باشد. تحقیقات نشان داده است که رقت های مهاری کورکومین بر روی شیگلا 256-80 میکروگرم در میلی‌لیتر و حداقل غلظت کشندگی آن 512 میکروگرم در میلی لیتر است. با توجه به اینکه کورکومین به عنوان یک ماده غذایی کاربرد فراوان دارد می توان از آن به عنوان داروغذا در شرایط بالینی استفاده کرد.
Shigella are gram-negative, motionless, spore-causing bacteria that cause a condition called shigellosis, or bacilli. Shigella Due to the low infectious dose (10-100 bacteria) and high side effects, the increase in antibiotic-resistant strains is significant. Shigellosis is the second leading cause of death in children under 5 years of age. Early diagnosis and antibiotic treatment play a key role in reducing complications and mortality. Curcumin is a phenolic compound extracted from Turmeric, which is due to the pharmacological and antibacterial properties of Turmeric. Recent studies have shown that Curcumin in appropriate doses inhibits Shigella growth. The aim of this study was to evaluate the anti-Shigella effect of Curcumin. The present study is a review research. Research has shown that the inhibitory dilutions of Curcumin on Shigella are 80-256 µg/ml and its minimum lethal concentration is 512 µg/ml. Due to the fact that Curcumin is widely used as a food, it can be used as a drug in clinical Conditions.
1- Zhi S, Parsons BD, Szelewicki J, Yuen YTK, Fach P, Delannoy S, et al. Iden-tification of Shiga-Toxin-Producing Shi-gella Infections in Travel and Non-Travel Related Cases in Alberta, Canada. Toxins (Basel). 2021;13(11):755.
2- Ranjbar R, Farahani A. Shigella: Antib-iotic-Resistance Mechanisms And New Horizons For Treatment. Infection and drug resistance. 2019;12:67-3137.
3- Muthuirulandi Sethuvel DP, Veeraragh-avan B, Vasudevan K, Devanga Ragupathi NK, Murugan D, Walia K, et al. Complete genome analysis of clinical Shigella strains reveals plasmid pSS1653 with resistance determinants: a triumph of hybrid approach. Gut pathogens. 2019;11:55.
3- Gorden J, Small PL. Acid resistance in enteric bacteria. Infection and immunity. 1993;61(1):7-364.
4- Payne SM, Wyckoff EE, Murphy ER, Oglesby AG, Boulette ML, Davies NM. Iron and pathogenesis of Shigella: iron acquisition in the intracellular environment. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 2006;19(2):80-173.
5- Page AL, Fromont-Racine M, Sansonetti P, Legrain P, Parsot C. Characterization of the interaction partners of secreted proteins and chaperones of Shigella flexneri. Mol Microbiol. 2001;42(4):45-1133.
6- Shen D-K, Saurya S, Wagner C, Nish-ioka H, Blocker AJ. Domains of the Shi-gella flexneri type III secretion system IpaB protein involved in secretion regulation. Infection and immunity. 2010;78(12):4999-5010.
7- Deldar A, Yakhchali B. The influence of riboflavin and nicotinic acid on Shigella sonnei colony conversion. Iranian journal of microbiology. 2011;3(1):13-20. [Persian]
8- Niyogi SK, Vargas M, Vila J. Prevalence of the sat, set and sen genes among diverse serotypes of Shigella flexneri strains isola-ted from patients with acute diarrhoea. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004;10(6):6-574.
9- Thompson CN, Duy PT, Baker S. The Rising Dominance of Shigella sonnei: An Intercontinental Shift in the Etiology of Bacillary Dysentery. PLoS neglected trop-ical diseases. 2015;9(6):e0003708.
10- Schroeder GN, Hilbi H. Molecular path-ogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clinical microbiology revie-ws. 2008;21(1):56-134.
11- Nasrollahi Boroujeni F, Deldar AA. The Study of the Stable Expression of IpaB, the Virulence Factor in Shigella Sonnei, in Terms of Simultaneous Expression of Cha-perone IpgC. Iranian Journal of Medical Microbiology. 2018;12(4):8-260. [Persian]
12- Sani M, Botteaux A, Parsot C, Sans-onetti P, Boekema EJ, Allaoui A. IpaD is localized at the tip of the Shigella flexneri type III secretion apparatus. Biochimica et biophysica acta. 2007;1770(2):11-307.
13- Man AL, Prieto-Garcia ME, Nicoletti C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology. 2004;113(1): 15-22.
14- Ghandian S, Sattari M, Nikbin VS, Aslani MM. Study of antibiotic susceptib-ility pattern and presence of ipaH gene among shigella strains isolated from sele-cted provinces in Iran. Pathobiology Res-earch. 2011;14(1):8-81. [Persian]
15- Kim SH, Lee SR, Kim KS, Ko A, Kim E, Kim YH, et al. Shiga toxin A subunit mutant of Escherichia coli O157:H7 relea-ses outer membrane vesicles containing the B-pentameric complex. FEMS immunol-ogy and medical microbiology. 2010;58(3): 20-412.
16- Cherla RP, Lee SY, Tesh VL. Shiga toxins and apoptosis. FEMS microbiology letters. 2003;228(2):66-159.
17- Lingwood CA. Shiga toxin receptor glycolipid binding. Pathology and utility. Methods in molecular medicine. 2003;73: 86-165.
18- Odumosu O, Nicholas D, Yano H, Langridge W. AB toxins: a paradigm switch from deadly to desirable. Toxins (Basel). 2010;2(7):45-1612.
19- Huang A, Friesen J, Brunton JL. Cha-racterization of a bacteriophage that carries the genes for production of Shiga-like toxin 1 in Escherichia coli. J Bacteriol. 1987; 169(9):12-4308.
20- Cao M, Wang W, Zhang L, Liu G, Zhou X, Li B, et al. Epidemic and molecular characterization of fluoroquinolone-resista-nt Shigella dysenteriae 1 isolates from calves with diarrhea. BMC microbiology. 2021;21(1):6.
21- Ahmadpour A, Fatahi E, Jafar A, Imani Fooladi AA, Tabar Molahassan A. Detection of Shigella dysenteriae STX1 gene from Mazandaran province clinical samples by PCR-ELISA method. Iranian Journal of Medical Microbiology. 2016; 10(5):9-11. [Persian]
22- Soltan Dallal MM, Sedighi Khavidak S, Rastegar S, Rajabi Z. The Frequency of Shigella Species in Acute Diarrhea caused by Consumption of Contaminated Food in Yazd province and Determination of its Antibiotic Resistance Factors. Tolooebeh-dasht. 2018;17(4):56-69. [Persian]
23- Kahsay AG, Muthupandian S. A review on Sero diversity and antimicrobial resis-tance patterns of Shigella species in Africa, Asia and South America, 2001-2014. BMC research notes. 2016;9(1):422.
24- Sahne F, Mohammadi M, D. Najafpour G, Moghadamnia AA. Optimization of the extraction of curcumin from turmeric (Cu-rcuma longa L.) using carbamate ionic liquid as green solvent. Innovative Food Technologies. 2017;4(4):1-12. [Persian]
25- Gopal J, Muthu M, Chun S-C. One-step, ultrasonication-mobilized, solvent-free ext-raction/synthesis of nanocurcumin from tur-meric. RSC Advances. 2015;5(60):8-48391.
26- Ansari E, Issazadeh K, Shoae Hassani A. A study to investigate antibacterial effect of Nanocurcumin against pre-clinical meth-icillin resistant staphylococcus aureus infe-ction. Journal of Microbial World. 2014; 7(1):26-37. [Persian]
27- Kareem SM, Mahmood SS, Hindi NK. Effects of Curcumin and Silymarin on the Shigella dysenteriae and Campylobacter jejuni In vitro. Journal of gastrointestinal cancer. 2020;51(3):8-824.
28- Foryst-Ludwig A, Neumann M, Schn-eider-Brachert W, Naumann M. Curcumin blocks NF-kappaB and the motogenic res-ponse in Helicobacter pylori-infected epith-elial cells. Biochemical and biophysical research communications. 2004;316(4): 72-1065.
29- Sintara K, Thong-Ngam D, Patumraj S, Klaikeaw N, Chatsuwan T. Curcumin sup-resses gastric NF-kappaB activation and macromolecular leakage in Helicobacter pylori-infected rats. World J Gastroenterol. 2010;16(32):46-4039.
30- Zaidi SF, Yamamoto T, Refaat A, Ahmed K, Sakurai H, Saiki I, et al. Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter. 2009;14(6):95-588.
31- Kaur S, Modi NH, Panda D, Roy N. Probing the binding site of curcumin in Escherichia coli and Bacillus subtilis FtsZ--a structural insight to unveil antibacterial activity of curcumin. European journal of medicinal chemistry. 2010;45(9):14-4209.
32- Bellio P, Brisdelli F, Perilli M, Sabatini A, Bottoni C, Segatore B, et al. Curcumin inhibits the SOS response induced by levofloxacin in Escherichia coli. Phytome-dicine: international journal of phytothera-py and phytopharmacology. 2014;21(4):4-430.
33- Liang Z, Liu X, Qin Z, Li J, Yu J, He X, et al. Photodynamic inactivation of Shigella flexneri by curcumin. LWT. 2022;153: 112491.
34- Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Advances in experimental medicine and biology. 2007;595:1-75.
35- Shariati A, Asadian E, Fallah F, Azimi T, Hashemi A, Yasbolaghi Sharahi J, et al. Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from bu-rn wound infection in Tehran, Iran. Infe-ction and drug resistance. 2019;12:35-2223.
36- De R, Kundu P, Swarnakar S, Ramam-urthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrobial agents and chemotherapy. 2009;53(4):7-1592.
37- Rafaat haghighi A, Borjian A, Rezaeian A, Shizadi. The Effect Of Antimicrobial Two Pharmaceutica Plant Salvia Mirzay-ianii Rech.F. And Haplophyllum Canalicul-atumboiss On Shigella dysenteriae. Journal of Microbial World. 2013;6(1):80-73. [Persian]
38- Alipour yeganeh M, Tahik H, Zadeh H, Farkhondeh T, Sadighara P, Sabah S. Inhibitory Effect Of Garlic Extract On The Growth Of Salmonella Typhimurium And Shigella dysenteric. Knowledge And Health. 2009;4(2). [Persian]
39- Mazumder R, Mendiratta T, Mondal SC, Mazumder A. Antimicrobial Potency of the Leaf - Stalk Extract of Curcuma longa (LINN). Ancient science of life. 2000;20(1-2):6-92.
40- Soleimani N. Molecular Biology of Aminoglycoside and Relationship of Aminoglycoside Modifying Enzymes with Altering Resistance. Alborz University Medical Journal. 2017;6(4):40-227. [Pers-ian]
41- Reda FM, El-Saadony MT, Elnesr SS, Alagawany M, Tufarelli V. Effect of Dietary Supplementation of Biological Curcumin Nanoparticles on Growth and Carcass Traits, Antioxidant Status, Imm-unity and Caecal Microbiota of Japanese Quails. Animals (Basel). 2020;10(5):754.
42- Alizadeh Sarvandani S, Amini K, Saffarian P. Evaluation of antimicrobial activity of Curcumin nanoparticles on the gene expression of the enterococcal surface protein, Esp, involved in biofilm formation of Enterococcus Faecalis. Razi Journal of Medical Sciences. 2019;26(9):39-46. [Pers-ian]
43- Liu TY, Tan ZJ, Jiang L, Gu JF, Wu XS, Cao Y, et al. Curcumin induces apoptosis in gallbladder carcinoma cell line GBC-SD cells. Cancer cell international. 2013;13(1): 64.
44- Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer research. 2001;21(4b): 900-2895.
_||_